Numerous clinical trials phase II and phase III

2019-04-15

Numerous clinical trials (phase II and phase III) have been then designed to evaluate the efficacy of denosumab in oncology mainly in breast and prostate bone metastases (Table 1). These studies revealed that denosumab reduced significantly bone turnover markers similarly to osteoporotic patients.

More recently Brugada et al used flecainide

2019-04-11

More recently, Brugada et al. [131]. used flecainide to identify the full extent of low-voltage electrogram activity in the anterior RV and RVOT and targeted this region for RFA. In all 14 BrS patients, RFA eliminated abnormal bipolar electrograms, normalized ST-segment elevation on right precordial

Hello world!

2018-07-29